<DOC>
	<DOCNO>NCT02988817</DOCNO>
	<brief_summary>The purpose trial establish tolerability HuMax-AXL-ADC mixed population patient specify solid tumor</brief_summary>
	<brief_title>HuMax-AXL-ADC Safety Study Patients With Solid Tumors</brief_title>
	<detailed_description>The trial consist two part ; dose escalation part ( phase I , first in- human ( FIH ) ) expansion part ( phase IIa ) . The dose escalation part two dose escalation arm : first arm investigate every 3 week ( 1Q3W ) dose schedule second one investigate three administration 4 week ( 3Q4W ) dose schedule . The Expansion part trial , explore recommend phase 2 dose HuMax-AXL-ADC determine Part 1</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>1 . For dose escalation part : Patients select , relapse solid tumor fail available standard therapy candidate standard therapy . 2 . For expansion part : Patients relapse , advance and/or metastatic solid tumor Patients must measurable disease . 3 . Age ≥ 18 year . 4 . Acceptable renal function 5 . Acceptable liver function 6 . Acceptable hematological status 7 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 8 . Life expectancy least three month . 9 . Patients , female male , childbearing/reproductive potential must agree use adequate contraception include trial six month last infusion HuMaxAXLADC 10 . Patients must provide sign informed consent form trial relate activity carry . 1 . Acute deep vein thrombosis clinically relevant pulmonary embolism , stable least 4 week prior first IMP administration . 2 . Have clinically significant cardiac disease 3 . Known congestive heart failure and/ know decreased cardiac ejection fraction &lt; 45 % . A baseline QT interval correct Fridericia 's formula ( QTcF ) &gt; 480 msec , complete leave bundle branch block ( define QRS interval ≥ 120 msec leave bundle branch block form ) incomplete leave bundle branch block . 4 . Uncontrolled hypertension 5 . Have receive granulocyte colony stimulate factor ( GCSF ) granulocyte/macrophage colony stimulate factor support 3 week prior first IMP administration . 6 . Have receive cumulative dose corticosteroid ≥ 150 mg prednisone ( equivalent dos corticosteroid ) within two week first Investigational Medicinal Product ( IMP ) administration . 7 . History ≥ grade 3 allergic reaction monoclonal antibody therapy well know suspect allergy intolerance agent give course trial . 8 . Major surgery within four week first IMP administration . 9 . Any history intracerebral arteriovenous malformation , cerebral aneurysm , brain metastasis stroke . 10 . Any anticancer therapy include ; small molecule , immunotherapy , chemotherapy monoclonal antibody experimental drug within five halflives maximum four week first infusion . Accepted exception bisphosphonates , denosumab gonadotropinreleasing hormone agonist antagonist . 11 . Prior therapy conjugate unconjugated auristatin derivative/vincabinding site target payload . 12 . Radiotherapy within 14 day prior first IMP administration . 13 . Known past current malignancy inclusion diagnosis , except : Cervical carcinoma Stage 1B less . Noninvasive basal cell squamous cell skin carcinoma . Noninvasive , superficial bladder cancer . Prostate cancer current PSA level &lt; 0.1 ng/mL . Breast cancer BRCA1 BRCA2 positive ovarian cancer patient . Any curable cancer complete response ( CR ) &gt; 2 year duration . 14 . Ongoing significant , uncontrolled medical condition include : Serious , nonhealing wound , skin ulcer ( grade ) , bone fracture . 15 . Grade 2 high peripheral neuropathy . 16 . Clinically significant active viral , bacterial fungal infection 17 . Known human immunodeficiency virus seropositivity . 18 . Known positive serology hepatitis B ( unless due vaccination passive immunization due immunoglobulin therapy ) 19 . Known positive serology hepatitis C ( unless due immunoglobulin therapy ) 20 . Substance abuse , medical , psychological social condition may interfere patient 's participation trial evaluation trial result 21 . History organ allograft ( except corneal transplant ) autologous allogeneic bone marrow transplant , stem cell rescue within 3 month prior first dose IMP 22 . Body weight &lt; 40 kg 23 . Women pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>